Reported net income in the quarter was $1.11 a share vs. $1.18 a share a year ago.
Revenue for the third quarter was better than expected, up 9% to $6.15 billion from $5.65 billion in a year ago. A consensus of analysts anticipated revenue of $6.06 billion.
The maker of Cymbalta and Cialis also sharpened earnings guidance for the full year to a range of $3.89 to $3.94 a share from previous guidance of $3.85 to $3.95 a share. The company pointed to health care reform measures and expiring patent on Zyprexa as important drags on growth. Offsetting these will be increasing sales of Alimta, Cialis, Cymbalta, Effient, Humalog and animal health products.Follow TheStreet on Twitter and become a fan on Facebook. Global sales of Zyprexa fell 3% to $1.18 billion, while sales of Cymbalta rose 29% to $1.07 billion. -- Written by Carlton Wilkinson.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV